| Current state of thrombolytic therapy. | |
| | |
MedLine Citation:
|
PMID: 10980844 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
More than 200,000 people have been enrolled into clinical trials examining different reperfusion strategies for patients with acute myocardial infarction. Each year approximately 1 million people in the United States experience acute myocardial infarction. Thrombolytic agents, including streptokinase and tissue-type plasminogen activator, activate plasminogen. These agents are often divided into "fibrin-specific" and "non-fibrin-specific" drugs. New thrombolytic agents designed to address several of the shortcomings of existing thrombolytics are in various stages of clinical development. |
| | |
Authors:
|
D A Vorchheimer |
Related Documents
:
|
9692644 - Timi grade flow, mortality, and the gusto-iii trial. 2807704 - Therapy for myocardial infarction: effect on trends in coronary disease mortality. 9585864 - Guidelines to reducing delays in administration of thrombolytic therapy in acute myocar... 10580214 - A community hospital's effort to expedite treatment for patients with chest pain. 128794 - Cardiomyopathy in the dog. 9692644 - Timi grade flow, mortality, and the gusto-iii trial. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current cardiology reports Volume: 1 ISSN: 1523-3782 ISO Abbreviation: Curr Cardiol Rep Publication Date: 1999 Sep |
Date Detail:
|
Created Date: 2000-12-20 Completed Date: 2000-12-20 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 212-20 Citation Subset: IM |
Affiliation:
|
Mt. Sinai Medical Center, Zena and Michael A. Wiener Cardiovascular Institute, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Fibrinolytic Agents
/
therapeutic use* Humans Myocardial Infarction / drug therapy*, epidemiology Myocardial Reperfusion Plasminogen Activators / therapeutic use Randomized Controlled Trials as Topic Recombinant Proteins / therapeutic use Streptokinase / therapeutic use Survival Analysis Thrombolytic Therapy* / methods Tissue Plasminogen Activator / therapeutic use Urokinase-Type Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Recombinant Proteins; 133652-38-7/reteplase; 153484-31-2/SUN 9216; 99149-95-8/saruplase; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low molecular weight heparin in acute coronary syndromes.
Next Document: Non-lipid-lowering effects of statins on atherosclerosis.